VIR - EC selects drugs from Lilly Incyte Regeneron GSK and Vir as preferred COVID treatments

bloodua/iStock via Getty Images The European Commission has selected five medications that its considers preferred therapies in the treatment of COVID-19, Reuters reports. The medicines include Eli Lilly (LLY) and Incyte's (INCY) Oluminant (baricitinib), Regeneron's (REGN) REGN-COV2 (casirivimab/ imdevimab), and GlaxoSmithKline (GSK)/Vir Biotechnology's (VIR) sotrovimab. Last week, the US Department of Health and Human Services HHS paused distribution of Lilly's bamlanivimab and etesevimab cocktail amid concerns it is not effective against certain COVID-19 variants.   The only COVID-19 treatment approved in the EU is Gilead's (GILD) Veklury (remdesivir). Lilly shares are up 0.8% to $230.01, Incyte shares are down 1% to $84.73, Regeneron shares are up 0.1% to $543.36, GSK shares are up 0.1% to $39.91 and Vir is up 1.5% to $47.58.

For further details see:

EC selects drugs from Lilly, Incyte, Regeneron, GSK, and Vir as preferred COVID treatments